Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 12/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.74 |
| ▸ | TNKS | O95271 | 2/20 | 0.65 |
| ▸ | PARP1 | P09874 | 2/20 | 0.65 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.65 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.56 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.51 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31066916 | 1.00 | GUSB (1.00) | GUSBHPGDKDM4ETNKSPARP1 | |
| SCHEMBL31066914 | 1.00 | GUSB (1.00) | GUSBHPGDKDM4ETNKSPARP1 | |
| SCHEMBL15691367 | 0.90 | GUSB (0.82) | GUSBHPGDKDM4ETNKSPARP1 | |
| SCHEMBL18258709 | 0.86 | GUSB (0.76) | GUSBHPGDKDM4ETNKSPARP1 | |
| SCHEMBL18258694 | 0.86 | GUSB (0.76) | GUSBHPGDKDM4ETNKSPARP1 | |
| SCHEMBL31710757 | 0.86 | GUSB (0.76) | GUSBHPGDKDM4ETNKSPARP1 | |
| SCHEMBL11746423 | 0.85 | GUSB (0.74) | GUSBHPGDKDM4ETNKSPARP1 | |
| SCHEMBL296097 | 0.85 | GUSB (1.00) | GUSBHPGDKDM4ETNKSPARP1 | |
| SCHEMBL29890314 | 0.85 | GUSB (1.00) | GUSBHPGDKDM4ETNKSPARP1 | |
| SCHEMBL30259689 | 0.85 | GUSB (1.00) | GUSBHPGDKDM4ETNKSPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256754-A1 | QUINAZOLINES AS B-GLUCURONIDASE NOVEL INHIBITORS | CHOUDHARY MUHAMMAD IQBAL (PK) | 2014-09-11 | — | — | US | disclosed |
| US-20140256754-A1 | QUINAZOLINES AS B-GLUCURONIDASE NOVEL INHIBITORS | CHOUDHARY MUHAMMAD IQBAL (PK) | 2014-09-11 | — | — | US | disclosed |
| US-20140256754-A1 | QUINAZOLINES AS B-GLUCURONIDASE NOVEL INHIBITORS | CHOUDHARY MUHAMMAD IQBAL (PK) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256754-A1 | QUINAZOLINES AS B-GLUCURONIDASE NOVEL INHIBITORS | GUSB, GBA3, GAA | GUSB 1/4885HPGD 1338/4885KDM4E 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.